Abstract
Our study demonstrates that silencing circASH1L alleviates cisplatin resistance in ovarian cancer cells. The underlying mechanism involves the upregulation of miR-515-5p, which targets the CDCA7/RRM2 axis, leading to cell cycle modulation and the induction of ferroptosis. Targeting the circASH1L/miR-515-5p/CDCA7 pathway offers new insights into the relationship between ferroptosis and chemoresistance, presenting a promising strategy to overcome chemoresistance in ovarian cancer.
Introduction
Ovarian cancer is notoriously difficult to treat due to late-stage diagnosis and a high recurrence rate of approximately 70%. While platinum-based chemotherapy (cisplatin) is the standard of care, many patients develop resistance. This research, published in Frontiers in Pharmacology, identifies circASH1L as a key circular RNA that protects cancer cells from ferroptosis—an iron-dependent form of oxidative cell death—thereby driving cisplatin resistance.
Methods
The study utilized a multi-disciplinary approach to map the molecular landscape of resistance:
- Identification: RNA sequencing (RNA-seq) on ovarian cancer cells treated with the ferroptosis inducer erastin identified circRNAs associated with cell death.
- Validation: The circular nature of circASH1L was confirmed using RNase R digestion and Sanger sequencing.
- Functional and Biochemical Assays: Researchers measured cell viability, invasion, and markers of ferroptosis, including iron ions, malondialdehyde (MDA), and glutathione (GSH).
- Mechanistic Mapping: Dual-luciferase reporter assays and immunoprecipitation (RIP and Co-IP) were used to confirm interactions within the circASH1L/miR-515-5p/CDCA7/RRM2 axis.
- In Vivo Models: Findings were validated using a xenograft mouse model to observe the effects of circASH1L silencing on tumor growth and drug sensitivity.
Key Results
circASH1L Upregulation and Drug Resistance
Experimental data revealed that circASH1L expression is significantly elevated in cisplatin-resistant cell lines. In SKOV3/DDP cells, circASH1L levels were approximately four times higher than in sensitive SKOV3 cells, suggesting its role in maintaining the resistant phenotype.
Clinical Impact and Survival Correlation
Analysis of patient data from TCGA and GEO databases established a clear link between circASH1L levels and clinical outcomes. High expression of circASH1L was found to correlate with significantly lower overall survival probabilities, highlighting its potential as a prognostic biomarker.
The Mechanistic Axis
The study identified a "sponge" mechanism where circASH1L sequesters miR-515-5p, which normally suppresses the oncogene CDCA7. By stabilizing CDCA7, circASH1L further stabilizes RRM2, a protein that inhibits ferroptosis. Silencing circASH1L restores sensitivity to cisplatin by triggering ferroptosis, evidenced by increased iron accumulation and oxidative stress markers.
Discussion
Targeting the circASH1L/miR-515-5p/CDCA7/RRM2 axis presents a novel therapeutic opportunity to overcome chemoresistance in ovarian cancer. While the study provides robust evidence in cell and animal models, future work must address the challenges of clinical delivery systems and the potential involvement of other redundant molecular pathways.
Summary updated